Stereotactic body radiotherapy for centrally located stage I nonsmall cell lung cancer

Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative body radiotherapy (SABR), has become the standard of care over the last decade for treating early stage non-small cell lung cancer (NSCLC) in patients who cannot undergo surgery (1). The technique allows for the delivery of very high doses of radiation with a goal of treating tumors with a biological effective dose (BED10) greater than 100 Gy (2). In order to achieve this safely, the planning process requires precise definition of the target, management of target motion, conformal planning with sharp dose fall off and high quality daily set-up verification